These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 38282155)

  • 1. miR-451a suppresses the proliferation and migration of high-grade serous ovarian cancer by targeting RAB5A through the Ras/Raf/MEK/ERK pathway.
    Liu S; Wang K; Zhao Z; Pang Y; Liu F; Wang P; Wang Z; Yang X
    J Gene Med; 2024 Jan; 26(1):e3649. PubMed ID: 38282155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-cancer effect of miR-139-3p on laryngeal squamous cell carcinoma by targeting rab5a: In vitro and in vivo studies.
    Ma Y; Gong Z; Wang H; Liang Y; Huang X; Yu G
    Pathol Res Pract; 2020 Nov; 216(11):153194. PubMed ID: 32916448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MiR-585-3p suppresses tumor proliferation and migration by directly targeting CAPN9 in high grade serous ovarian cancer.
    Lu X; Li G; Liu S; Wang H; Chen B
    J Ovarian Res; 2021 Jul; 14(1):90. PubMed ID: 34238324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. miRNA-651-3p regulates EMT in ovarian cancer cells by targeting ZNF703 and via the MEK/ERK pathway.
    Wang S; Wang C; Liu O; Hu Y; Li X; Lin B
    Biochem Biophys Res Commun; 2022 Sep; 619():76-83. PubMed ID: 35749939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Propofol suppresses cell viability, cell cycle progression and motility and induces cell apoptosis of ovarian cancer cells through suppressing MEK/ERK signaling via targeting circVPS13C/miR-145 axis.
    Lu H; Zheng G; Gao X; Chen C; Zhou M; Zhang L
    J Ovarian Res; 2021 Feb; 14(1):30. PubMed ID: 33563314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MiR-451a suppresses cell proliferation, metastasis and EMT via targeting YWHAZ in hepatocellular carcinoma.
    Wei GY; Hu M; Zhao L; Guo WS
    Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5158-5167. PubMed ID: 31298411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNA-625-3p improved proliferation and involved chemotherapy resistance via targeting PTEN in high grade ovarian serous carcinoma.
    Zhong L; Liu X; Wang L; Liu Y; Zhang D; Zhao Y
    J Ovarian Res; 2022 Jan; 15(1):7. PubMed ID: 35027053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Propofol Represses Cell Growth and Metastasis by Modulating the Circular RNA Non-SMC Condensin I Complex Subunit G/MicroRNA-200a-3p/RAB5A Axis in Glioma.
    Zhang L; Chen H; Tian C; Zheng D
    World Neurosurg; 2021 Sep; 153():e46-e58. PubMed ID: 34129971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rab5a is overexpressed in oral cancer and promotes invasion through ERK/MMP signaling.
    Zhang D; Lu C; Ai H
    Mol Med Rep; 2017 Oct; 16(4):4569-4576. PubMed ID: 28849149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. miR-451a suppresses papillary thyroid cancer cell proliferation and invasion and facilitates apoptosis through targeting DCBLD2 and AKT1.
    Tan J; Li C; Ren L; Zhu X; Hua F; Fu Y
    Mol Cell Probes; 2022 Dec; 66():101863. PubMed ID: 36252912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNA-18a suppresses ovarian carcinoma progression by targeting CBX7 and regulating ERK/MAPK signaling pathway and epithelial-to-mesenchymal transition.
    Zhao Y; Liu XL; Huang JH; Yin AJ; Zhang H
    Eur Rev Med Pharmacol Sci; 2020 May; 24(10):5292-5302. PubMed ID: 32495862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mex3a promotes oncogenesis through the RAP1/MAPK signaling pathway in colorectal cancer and is inhibited by hsa-miR-6887-3p.
    Li H; Liang J; Wang J; Han J; Li S; Huang K; Liu C
    Cancer Commun (Lond); 2021 Jun; 41(6):472-491. PubMed ID: 33638620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long non-coding RNA SNHG16 regulates cell behaviors through miR-542-3p/HNF4α axis via RAS/RAF/MEK/ERK signaling pathway in pediatric neuroblastoma cells.
    Deng D; Yang S; Wang X
    Biosci Rep; 2020 May; 40(5):. PubMed ID: 32412051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting RAS-ERK pathway alterations with MEK inhibitors to improve chemosensitivity in high grade serous ovarian cancers.
    Nguyen NT; Raetz A; Montoya D; Schilling V; Tong C; Brooks RA; Leiserowitz G; Chien J
    Gynecol Oncol; 2023 Nov; 178():69-79. PubMed ID: 37806229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNA-338-3p suppresses ovarian cancer cells growth and metastasis: implication of Wnt/catenin beta and MEK/ERK signaling pathways.
    Zhang R; Shi H; Ren F; Feng W; Cao Y; Li G; Liu Z; Ji P; Zhang M
    J Exp Clin Cancer Res; 2019 Dec; 38(1):494. PubMed ID: 31842953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circ_0070203 Promotes Epithelial-mesenchymal Transition in Ovarian Serous Cystadenocarcinoma through miR-370-3p/TGFβR2 Axis.
    Tang Q; Wen H; Hu H; Chen X; Xu S; Fan L; Liu L; Li J
    Recent Pat Anticancer Drug Discov; 2024; 19(2):233-246. PubMed ID: 38214360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA-130a inhibits cell proliferation, invasion and migration in human breast cancer by targeting the RAB5A.
    Pan Y; Wang R; Zhang F; Chen Y; Lv Q; Long G; Yang K
    Int J Clin Exp Pathol; 2015; 8(1):384-93. PubMed ID: 25755726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA-30a suppresses tumor progression by blocking Ras/Raf/MEK/ERK signaling pathway in hepatocellular carcinoma.
    Zhou K; Luo X; Wang Y; Cao D; Sun G
    Biomed Pharmacother; 2017 Sep; 93():1025-1032. PubMed ID: 28732393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biological and prognostic value of ETV5 in high-grade serous ovarian cancer.
    Zhang L; Fu R; Liu P; Wang L; Liang W; Zou H; Jia W; Tao L
    J Ovarian Res; 2021 Nov; 14(1):149. PubMed ID: 34736492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long non‑coding RNA CASC19 promotes glioma progression by modulating the miR‑454‑3p/RAB5A axis and is associated with unfavorable MRI features.
    Wu YJ; Yang QS; Chen H; Wang JT; Wang WB; Zhou L
    Oncol Rep; 2021 Feb; 45(2):728-737. PubMed ID: 33416169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.